Loading…
Utah Medical Products, Inc. is projected to rise to $77.97 by 2027, a +19% move from its current price of $65.54. UTMD is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $64.94 | $65.56 | $66.18 | +0.02% |
| May 30 | $64.70 | $65.57 | $66.45 | +0.05% |
| May 31 | $64.53 | $65.59 | $66.67 | +0.07% |
| Jun 1 | $64.38 | $65.60 | $66.85 | +0.10% |
| Jun 2 | $64.25 | $65.62 | $67.02 | +0.12% |
| Jun 3 | $64.14 | $65.63 | $67.17 | +0.14% |
| Jun 4 | $64.03 | $65.65 | $67.31 | +0.17% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $64.03 | $65.65 | $67.31 | +0.17% |
| Week 2 | $63.48 | $65.76 | $68.12 | +0.34% |
| Week 3 | $63.09 | $65.87 | $68.78 | +0.51% |
| Week 4 | $62.77 | $65.98 | $69.36 | +0.68% |
| Week 5 | $62.51 | $66.09 | $69.89 | +0.85% |
| Week 6 | $62.28 | $66.21 | $70.38 | +1.02% |
| Week 7 | $62.08 | $66.32 | $70.84 | +1.19% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Utah Medical Products, Inc. (UTMD) is a healthcare company that develops and offers medical devices for the healthcare industry in the United States, Europe, and internationally. Incorporated in 1978 and headquartered in Midvale, Utah, it serves hospitals, clinics, and physician offices with a broad portfolio of devices and systems.
UTMD trades as a healthcare stock with a current price of $64.51 and a market cap of $205.4M. It is ranked 3830 by market capitalization in its sector. The stock sits near its near-term moving average, with the SMA50 at $65.18 and the SMA200 at $61.46, indicating a constructive position relative to its longer-term trend.
A major floor 9.7% below — a decisive break under it would weaken the trend.
The nearest floor, 3.4% below — buyers have tended to step in here.
The nearest ceiling, 7.8% above — a clean break opens room to run.
A major ceiling 12.6% above — clearing it would confirm fresh momentum.
Key UTMD support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of UTMD market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $64.89 | Buy | $64.96 | Buy |
| MA 10 | $64.35 | Buy | $64.74 | Buy |
| MA 20 | $64.61 | Buy | $64.91 | Buy |
| MA 50 | $65.25 | Buy | $64.92 | Buy |
| MA 100 | $64.05 | Buy | $63.84 | Buy |
| MA 200 | $61.56 | Buy | $62.36 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 53.53 | Neutral |
| Stoch RSI (14) | 100.00 | Sell |
| CCI (20) | 101.23 | Buy |
| Williams %R (14) | 0.00 | Info |
| MACD (12,26,9) | 0.13 | Buy |
| ROC (12) | 0.29 | Buy |
| Bollinger %B (20,2) | 0.84 | Neutral |
| Stochastic %K (14) | 100.00 | Sell |
| TRIX (15) | -0.10 | Sell |
| Awesome (5,34) | -1.14 | Sell |
| Ultimate (7,14,28) | 70.60 | Sell |
| Momentum (10) | 1.72 | Buy |
| Aroon Osc (25) | -68.00 | Sell |
| Hull MA (9) | 65.38 | Buy |
| ADX (14) | 12.44 | Neutral |
| ATR (14) | 0.56 | Info |
The 30-day technical picture shows a bullish tilt in the near term. RSI14 is 50, and the price is hovering around the SMA50 of $65.18 while above the SMA200 of $61.46.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $56.50 | $65.54 | $86.64 | 0% | Neutral | |
| $63.69 | $77.97 | $99.90 | +19% | Neutral | |
| $72.41 | $90.25 | $118.66 | +38% | Bullish | |
| $83.59 | $105.76 | $141.95 | +61% | Bullish | |
| $97.78 | $125.37 | $171.24 | +91% | Bullish | |
| $108.55 | $140.86 | $195.39 | +115% | Bullish | |
| $112.07 | $147.06 | $206.86 | +124% | Bullish | |
| $119.58 | $158.55 | $225.88 | +142% | Bullish | |
| $122.51 | $164.05 | $236.49 | +150% | Bullish | |
| $132.78 | $179.47 | $261.57 | +174% | Bullish | |
| $197.24 | $278.01 | $424.49 | +324% | Bullish | |
| $388.05 | $586.50 | $959.68 | +795% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $56.50 | $65.54 | $77.04 | +0.00% |
| June 2026 | $58.02 | $67.68 | $80.49 | +3.27% |
| July 2026 | $57.10 | $67.00 | $80.42 | -1.02% |
| August 2026 | $56.81 | $66.96 | $80.96 | -0.06% |
| September 2026 | $58.19 | $68.84 | $83.73 | +2.81% |
| October 2026 | $58.31 | $69.21 | $84.64 | +0.54% |
| November 2026 | $57.45 | $68.40 | $84.04 | -1.18% |
| December 2026 | $58.80 | $70.20 | $86.64 | +2.64% |
Click any year to see its month-by-month UTMD forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, UTMD is projected to trade between $56.50 and $86.64, averaging $65.54 — a potential gain of 0% from today's $65.54. A consolidation phase looks the most probable path here.
Utah Medical Products, Inc.'s 2027 outlook centres on $77.97, within a $63.69 to $99.90 range. That is up +19% on the projected 2026 average. That marks a +19% change versus current levels. Price action looks broadly range-bound.
By 2028, UTMD could reach as high as $118.66, with a base case around $90.25 and support toward $72.41 — roughly +38% from $65.54. Buyers look set to stay in control over this stretch.
Expect UTMD to range from $83.59 to $141.95 through 2029. The $105.76 average target implies a +61% move from current prices. That is up +17% on the projected 2028 average. Momentum favours further upside here.
The UTMD price prediction for 2030 points to an average of $125.37 (low $97.78, high $171.24) — a potential gain of +91% on today's $65.54. Buyers look set to stay in control over this stretch.
In 2031, UTMD is projected to trade between $108.55 and $195.39, averaging $140.86 — a potential gain of +115% from today's $65.54. That is up +12% on the projected 2030 average. Momentum favours further upside here.
Utah Medical Products, Inc.'s 2032 outlook centres on $147.06, within a $112.07 to $206.86 range. That is up +4% on the projected 2031 average. That marks a +124% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, UTMD could reach as high as $225.88, with a base case around $158.55 and support toward $119.58 — roughly +142% from $65.54. Momentum favours further upside here.
Expect UTMD to range from $122.51 to $236.49 through 2034. The $164.05 average target implies a +150% move from current prices. That is up +3% on the projected 2033 average. Buyers look set to stay in control over this stretch.
The UTMD price prediction for 2035 points to an average of $179.47 (low $132.78, high $261.57) — a potential gain of +174% on today's $65.54. Momentum favours further upside here.
In 2040, UTMD is projected to trade between $197.24 and $424.49, averaging $278.01 — a potential gain of +324% from today's $65.54. That is up +55% on the projected 2035 average. Buyers look set to stay in control over this stretch.
Utah Medical Products, Inc.'s 2050 outlook centres on $586.50, within a $388.05 to $959.68 range. That is up +111% on the projected 2040 average. That marks a +795% change versus current levels. Momentum favours further upside here.
Investing $1,000 in UTMD today (≈ 15.257858 UTMD) could be worth
$8,948.79
+$7,948.79 (+795%) by 2050 · US Dollar
Based on the average projected UTMD price of $586.5 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in UTMDwould be worth at today's price.
$1,000 invested in UTMD on May 27, 2025 (≈ 18.291568 UTMD) would be worth
$1,198.83
+$198.83 (+19.9%) today · 1.20× · US Dollar
Based on a UTMD entry price of $54.67 vs. today's $65.54.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $64.17 | $1,021.35 | +2.1% |
| 1 month ago | $66.78 | $981.43 | -1.9% |
| 3 months ago | $66.56 | $984.68 | -1.5% |
| 6 months ago | $56.35 | $1,163.09 | +16.3% |
| 1 year ago | $54.67 | $1,198.83 | +19.9% |
| All time (5.0y) ago | $85 | $771.06 | -22.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our UTMD forecast.
Our base-case forecast reaches $130.00 around 2031.
Implied market cap at $130.00: $413.92M
The multi-year forecast paints a strong upside trajectory. The 2026 average price is $64.51, rising to $123.57 by 2030, with a max of $168.81 and an ROI of 91.5%. By 2040, the average climbs to $274.00 with a max of $418.41 and a ROI of 324.7%, and by 2050 the average reaches $583.99 with a max of $955.64 and a ROI of 805.3%.
The sentiment shifts from Neutral in 2026–2027 to Bullish from 2028 onward, reflecting steadily rising fundamentals reflected in the forecast. These are estimates, not guarantees, and actual results may differ due to market conditions and other factors.
Tap a question to reveal the answer.
The forecast for 2030 shows an avg price of $123.57, a min of $96.36, a max of $168.81, with an ROI of 91.5%.
The long-term forecast indicates bullish momentum from 2028 onward, with the avg price rising to $123.57 by 2030 and up to $583.99 by 2050, corresponding to an ROI up to 805.3%. These are estimates and not guarantees.
No. The 2031 max price is $192.72, below $200. The forecast does project higher prices later, with a max of $418.41 by 2040 and $955.64 by 2050.
Current price is $64.51 and market cap is $205.4M.
RSI14 is 50; SMA50 is $65.18; SMA200 is $61.46; 30-day range is $60.52–$68.77; support is $63.34 and resistance is $70.65; annualized volatility is 20%.
Utah Medical Products, Inc. Community Discussion
0Share your Utah Medical Products, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.